Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eciskafusp alfa plus BCG in BCG-unresponsive high-risk non-muscle invasive bladder cancer
NL-OMON59815Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2025
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of eciskafusp alfa and bcg vaccine in bladder cancer and Bladder cancer in situ (CIS) (3 arms), sponsored by Roche. Primary endpoints: Incidence, nature, and severity of adverse events, Dose-limiting toxicities and 2 more. Started Apr 2025; status: completed.
02
Drugs
eciskafusp alfabcg vaccine
03
Conditions
bladder cancerBladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON59815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59815.